Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Stockhunter100on Mar 19, 2020 12:24pm

102 Views

Post# 30826656

Short Selling

Short Sellling is getting banned due to the current situation. Not yet in Canada but it will come and everyone in the financial industry is taking advantage of this: the sell pressure is high, Share price goes down drastically, shorts are covering at the same time , the industry is buying back for a cheap price. The timing would be perfect for the industry where even if they would have a short selling ban they won't be stuck.

Any Comments are appreciated

GLTA

Bullboard Posts

Debt-free cannabis company set for next stage of growth